From GlobeNewswire: 2025-06-02 19:30:00

Ascentage Pharma presented new clinical data on the MDM2-p53 inhibitor alrizomadlin at the ASCO Annual Meeting, showing promising antitumor activity in patients with advanced adenoid cystic carcinoma (ACC) and solid tumors. The drug demonstrated efficacy as both a monotherapy and in combination with toripalimab. Results from the study highlighted the potential of alrizomadlin to offer a new treatment strategy for patients with ACC and other rare cancer types like MPNST and LPS. The data presented at ASCO 2025 underscored the therapeutic potential of alrizomadlin and its synergistic effects with immunotherapies for various solid tumors.



Read more at GlobeNewswire: Live from ASCO 2025 | Ascentage Pharma Releases Promising